Cure My Disease

Don't miss your cure!

 Log in / Sign up

New cancer pill shows early promise, but trial halted

NCT ID NCT03114319

Terminated Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tested an oral drug called TNO155, alone or with another drug (nazartinib), in 227 adults with advanced solid tumors like lung cancer, melanoma, and head/neck cancer. The main goal was to check safety and find the right dose. The study was terminated early, so results are limited and no clear benefit has been shown yet.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

TNO155 (a SHP2 inhibitor) taken orally, alone or with nazartinib

What this could lead to

If successful, this could point toward a new treatment option for certain advanced cancers like lung or skin cancer.

What could go wrong

This was a very early (Phase 1) trial that was terminated, so it's unclear if the drug is safe or effective. Many early cancer drugs fail to show benefit.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cutaneous melanoma esophageal squamous cell carcinoma gastrointestinal stromal tumor head and neck squamous cell carcinoma melanoma neoplasm non-small cell lung carcinoma Noonan syndrome Squamous Cell Carcinoma of Head and Neck

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED EGFR MUTANT NON SMALL CELL LUNGCANCER (NSCLC) ADVANCED GASTROINTESTINAL STROMAL TUMORS (GIST) ADVANCED NRAS/BRAFT WT CUTANEOUS MELANOMA ESOPHAGEAL SQUAMOUS CELL CANCER (SCC) HEAD/NECK SCC KRAS G12-MUTANT NSCLC MELANOMA

Contacts and locations

Locations

  • Dana Farber Cancer Center

    Boston, Massachusetts, 02215, United States

  • H Lee Moffitt Cancer Center and Research Institute

    Tampa, Florida, 33612, United States

  • Memorial Sloane Ketterin Cancer Ctr

    New York, New York, 10065, United States

  • Novartis Investigative Site

    Toronto, Ontario, M5G 2M9, Canada

  • Novartis Investigative Site

    Milan, MI, 20141, Italy

  • Novartis Investigative Site

    Kobe, 650-0017, Japan

  • Novartis Investigative Site

    Rotterdam, South Holland, 3015 GD, Netherlands

  • Novartis Investigative Site

    Amsterdam, 1066 CX, Netherlands

  • Novartis Investigative Site

    Singapore, 168583, Singapore

  • Novartis Investigative Site

    Seoul, 03080, South Korea

  • Novartis Investigative Site

    Seoul, 05505, South Korea

  • Novartis Investigative Site

    L'Hospitalet de Llobregat, Barcelona, 08907, Spain

  • Novartis Investigative Site

    Barcelona, Catalonia, 08035, Spain

  • Novartis Investigative Site

    Madrid, 28009, Spain

  • Novartis Investigative Site

    Madrid, 28034, Spain

  • Novartis Investigative Site

    Madrid, 28040, Spain

  • Novartis Investigative Site

    Taipei, 10002, Taiwan

  • Sarah Cannon Research Institute

    Nashville, Tennessee, 37221, United States